The Product & Company Valuation course is designed to teach a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals, or strategic development decisions in the pharma-biotech world. This introductory course is very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors which shape the risk profile of the company in question. This course optimally balances interactive lectures with practical group work exercises that are designed to help you practice the fundamental valuation tools & techniques taught throughout the day. Valuation is an inherently subjective task, which is made even more difficult in the life science industry due to its unique challenges: high attrition rates in R&D, long investment cycle, complex technologies, IP situations, etc. Therefore, traditional valuation methods are not suitable. Of particular value in this course is the “Product Valuation and Deal Structuring” module where registrants will learn the commonly used rNPV (i.e., risk-adjusted Net Present Value) method for calculating the value of a drug in development. Subsequently, you will practice how to structure a licensing deal between companies. Registrants will use an Excel-based tool designed specifically for this module, which can be taken home for future use.

The Redefining Early-Stage Investments (RESI) conference series brings together start-ups with early-stage investors and strategic channel partners to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. RESI is cross-border and cross-domain, connecting start-ups with ten categories of global investors across the silos of drugs, devices, diagnostics, and digital health. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek seed, series A, and B funding.

The BIO International Convention attracts 15,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy.

The Biotech CEO Summits are unlike most meetings CEOs attend. It is not an investor conference nor is it a business development conference. Rather, the Summits’ focus is on the CEOs and the challenges they have leading their companies. The program is modeled after a think tank-style meeting with discussions led by subject matter experts with input from the CEOs. The CEOs benefit from the wisdom and experiences shared by other participating CEOs and the discussants. The Summits operate under Chatham House Rules to encourage open and frank conversations. The number of participants is limited to allow full engagement. Registration is not open; one has to be asked to join this event. The Summits are closed to media and the sessions are not recorded in order to provide an extra layer of privacy.

BIO Asia–Taiwan is Asia's largest biotech networking event, and is jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO). The BIO Asia–Taiwan International Conference and Exhibition was held for the first time in 2019. An endorsement of Taiwan's standing as a leading Asian biomedical industry hub, the gathering was a resounding success.

Biotechgate Digital Partnering is a virtual conference designed to support the business development of Biotech, Medtech and Pharma companies. Join five days of digital partnering and establish new global connections thanks to pre-arranged one-on-one Zoom meetings, along with informal networking events and workshops.

LINGMED LIMITED SHANGHAI together with Venture Valuation is pleased to invite you to a full-day workshop on Pharma-Biotech Product and Company Valuation. The course will help you: Understand the valuation concepts and techniques that are commonly applied in the pharma and biotech world Know how to assess and calculate the value of a biotech company Learn how to calculate the value of a pharmaceutical in development and how to structure a licensing deal

ChinaBio Partnering Forum is the premier life science partnering event in China. The event will attract biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.

Back for its 23rd Annual Edition, this global bio-pharma industry event will address the main challenges in investment for 2023 as well as partnering and alliance management and prospects for 2024. Key players will contribute their insights in panels, which will cover the macro picture as well as innovation in different therapeutic sectors. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. The main programme for the 23rd Annual BEF is spread throughout 2 days (20th - 21st of September) and will feature more than 15 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated parallel presentation tracks, alongside virtual company showcases, which will be available on demand during the virtual week. We anticipate 650+ delegates will register for the forum from all sectors of Life Sciences, with the target audience being corporate and financial investors/partners, banks and advisors, with part of the audience participating virtually.

An Introductory Course Understand the valuation concepts and techniques that are commonly applied in the pharma and biotech world – Know how to assess and calculate the value of a biotech company – Learn how to calculate the value of a pharmaceutical in development and how to structure a licensing deal.

BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. 34% of our delegates came from outside of Spain. This year, BIOSPAIN goes back to Barcelona, the main biotech cluster in Spain and one of the most dynamic cities in the world. The event will take place in Pavilion 1 – Fira de Barcelona – Montjuïc. It stands in a superb location in the city center, easily accessible from the airport and well-connected to the public transport network. It is located in Montjuïc Park, an area of cultural and historical interest thanks to its museums and theatres and it also features some of the main tourist attractions in Barcelona.

BioFuture is where relentless therapeutic pioneers, innovators, and investors gather to assess and shape the future of healthcare and digital health. Participate in candid, unfiltered discussions. At this year’s summit, we’ll explore the exciting mashup between rapidly evolving fields including biopharma, digital medicine, big data, AI, healthcare systems, payors, and more. The coming decade will dramatically accelerate the transformation of the healthcare ecosystem. Be part of the discussions that will shape and transform the future of healthcare.

AusBiotech is Australia’s annual flagship industry conference and will continue to advance the biotech community with local and international industry leaders building relationships and having the opportunity to recharge, re-energise and refresh. Last year’s programme saw more than 1,000 delegates and over 150 speakers and chairs, as we reflected on what our sector achieved and networked face-to-face. AusBiotech 2023 will be held at the Brisbane Convention & Exhibition Centre from Wednesday 1 November to Friday 3 November 2023.

BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.

An Introductory Course: Understand the valuation concepts and techniques that are commonly applied in the pharma and biotech world – Know how to assess and calculate the value of a biotech company – Learn how to calculate the value of a pharmaceutical in development and how to structure a licensing deal.